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Cancer screening is well-established in high income countries, but its evidence base is 
constantly evolving and often contentious. This leaves physicians and policymakers in a 
difficult position, forced to act in the context of methodological complexity and substantive 
disagreement.1,2 Three cases of screening for cancer or cancer risk are considered: cervical, 
prostate and breast screening. The unique characteristics of the disease, test and program 
in each case are outlined in Table 1. Tables 2-4, catalogue sources of controversy in each 
case; these are discussed in more depth below. The concluding section presents five 
common themes that may help explain the ongoing controversies.  
 
The aim is not to synthesize the evidence, but to provide the ‘backroom’ story of the 
evidence on cancer screening, and so illuminate why experts so often disagree.   
 
Cervical screening 
Cervical screening is one of the best-supported and least controversial forms of cancer 
screening. Nonetheless, there are potentially contentious features of the cervical screening 
evidence base. These are: 
 
1) Dependence on observational data; 
2) Understanding, communicating and managing the balance of benefit and harm; and 
3) The uncertain future impact of new technologies. 
 
The first challenge in the cervical screening evidence base is the status of the existing 
evidence. Screening was established in parts of Europe and North America between the late 
1940s and early 1960s and data from those programs, rather than from controlled trials, 
provide the evidence base for cervical screening effectiveness. Observational studies 
compared screened and unscreened populations and showed reduced cervical cancer 
incidence and mortality in the former.3-5 This evidence base clearly shows that cervical 
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screening reduces morbidity and mortality: what is less clear is who to screen, when, and 
how to optimize benefit and minimize harm.  
 
The cervical screening evidence base is susceptible to the well-known biases of any 
observational study.1 It is not clear how these likely biases should be taken into account. In 
addition, the observational data about cervical screening crosses jurisdictions in which there 
are substantially different programs and reporting standards. This means that these 
observational data from different settings may not be as easily comparable as is often 
assumed (Table 1). To minimize bias, meta-analysis of Randomized Controlled Trial (RCT) 
evidence is the preferred method for estimating benefit and harm in screening. RCT 
evidence of different screening technologies, and combinations of technologies, is 
emerging. This may add more certainty to the cervical screening evidence base, although 
some of the findings from RCTs in low and middle income countries (LMICs) may not be 
transferable to other settings.6-9  
Table 1: Disease, test and program characteristics in each case 
 Cervical cancer Prostate cancer Breast cancer 
Tests used Pap smear using 
conventional &/or liquid 
based cytology +/- 
computer-assisted reading. 
HPV DNA testing increasing 
+/- cytology. Visual 
inspection with acetic 
acid/liquid iodine (VIA/VILI) 
in LMICs.  
PSA test. 
New testing methods, 
including use of 
biomarkers, are being 
developed. DRE also used. 
Mammogram. Fixed or 
mobile mammogram unit; 
recently widely upgraded to 
digital technology. 
When test was 
invented 
Pap test developed late 
1930s. 
First commercial PSA test 
released in 1986. 
X-ray used for breast 
disease 1910s; 1
st
 screening 
RCT 1963-75.  
When test was first 
used for screening 
Used to screen 
asymptomatic women 
from the 1940s. 
USFDA approved PSA test 
for prostate cancer 
screening in 1994.  
Ad hoc screening from mid 
20
th
 century;
60
 population 
screening programs 1980s 
onwards (based on 
publication of results from 
early RCTs). 
What test is 
designed to detect 
Abnormal cells on the 
cervix (cytology,  VIA/VILI) 
OR Presence of oncogenic 
HPV strains (HPV test).  
Raised serum PSA levels. Variations in soft tissue 
radiolucency.  Originally 
diagnostic. 
Relationship 
between test and 
target disease? 
HPV-caused lesions are 
potential precursors for 
cervical cancer.  
Poor. Test not developed 
to screen for cancer. 
Elevated PSA may not 
indicate cancer risk.  
Cancers have characteristic 
(often subtle) soft tissue 
appearances on x-ray. 
What results of 
screening are 
reported 
Lesions: nature & severity 
(grade) of changes. 
Reporting standards differ. 
HPV reported by type. 
Prostate Specific Antigen 
levels, expressed as 
nanograms of PSA per 
millilitre (ng/ml) of blood.  
Apparent presence of 
masses and lesions 
suspicious for invasive 
and/or in situ cancer. 
Contention over 
test itself 
Cytology is prone to human 
error. Terminology & 
reporting standards vary. 
Sensitivity & specificity 
estimates vary widely.
61
  
There is no meaningful 
‘normal range’ for the PSA 
test in screening. 
There is variation in what 
degree of suspicion 
constitutes a positive 
screen. 
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Variations between  
jurisdictions that 
may change the 
evidence base 
regarding benefit 
and/or harm 
IARC recommends 3-yrly 
cytology screening from 
25yrs. Evidence base pools 
data from widely varied 
programs:
5 
start-age 
ranges from 18-30yrs, 
interval 1-5yrs; reporting 
standards, terminology & 
treatment vary. 
Differences in target age, 
recommended finishing 
ages, screening intervals, 
thresholds definition of 
“abnormal”, biopsy 
thresholds. 
Differences in target age, 
screening intervals, 
thresholds for recall & 
biopsy. 
Service studies may differ 
in: participant population 
age (and therefore 
underlying cancer risk), 
follow-up, out-of-study 
screening. 
Developments in 
the test 
Tests that detect 
oncogenic-type HPV may 
supersede cytology as 
primary screening test. 
New test rules in 
development. Variations 
proposed (free: total PSA 
ratio, PSA density, velocity, 
doubling time, prostate 
health index) for clinical 
significance. No evidence 
these improve health 
outcomes 
2
. 
Increasing use of 
tomosynthesis (integrated 
2/3D mammography) and 
MRI which may contribute 
to both benefits and harms. 
Table Legend: DRE Digital Rectal Examination; HPV Human Papillomavirus; IARC International Agency for 
Research on Cancer; LMICs Low and Middle Income Countries; MRI Medical Resonance Imaging; PSA Prostate 
Specific Antigen; RCT Randomized Controlled Trial; USFDA US Food and Drug Administration; VIA visual 
inspection of the cervix using acetic acid to highlight precancerous lesions; VILI visual inspection of the cervix 
using Lugol’s iodine to highlight precancerous lesions. 
 
The second challenge in this evidence base concerns understanding, communicating and 
managing the balance of benefit and harm: this problem has several dimensions. It is easy to 
inadvertently overstate the mortality benefit of cervical screening, particularly in high-
income countries. This is because mortality from cervical cancer in high-income countries is 
considerably lower than for cancers such as breast and prostate. This was true even prior to 
widespread Pap-smear testing.  For example the age-standardized mortality rate from 
cervical cancer in the UK was approximately 8/100,000 in 1971, compared to 37.5/100,000 
for breast cancer and 20/100,000 for prostate cancer.10 Thus, even substantial proportional 
(or relative risk) reductions in mortality attributed to screening may represent only small 
reductions in the absolute number of deaths prevented in well-resourced countries (Table 
2). Cervical cancer, however, remains a significant burden and leading cause of cancer 
mortality in some low-income regions.11 
Table 2: Main issues in cervical cancer screening 
Issue Explanation 
Incidence and mortality of 
cervical cancer is low in 
high income countries 
The incidence of cervical cancer is much lower than e.g. breast or prostate 
cancer, so number needed to screen over many years to avoid one death is 
high.
12
  
Cervical screening reduces 
morbidity and mortality 
from cervical cancer. 
Early Nordic observational studies suggest a mortality benefit from screening 
using the Pap test. 
Organised programs confer greater benefit than opportunistic screening.
5
  
There is no RCT evidence 
from high income countries 
Because Pap test screening for cervical cancer was introduced so early, it was 
not possible or ethical to conduct an RCT of its effectiveness. 
RCTs are being conducted in 
LMICs  
These will be a useful evidence base for LMICs. 
It is easy to overstate the 
benefits of cervical cancer 
screening because the 
Because incidence is low, number needed to screen is high and absolute risk 
reduction low. 
Statements of benefit may obscure the relatively small absolute number of 
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underlying mortality rate is 
low 
people affected. For example mortality is often said to have halved in the 
decade following commencement of organised screening in Australia: this is 
accurate, but the absolute change was from only 4/100,000 to 2/100,000 
women. 
Most cervical lesions 
regress 
It has been recognised since the 1970s that most cervical lesions will not 
progress to cervical cancer.  
It is not clear what 
proportion of lesions 
regress, or which lesions 
will regress 
It may never become clear which lesions will regress or what proportion of 
them will regress. 
CIN3 progression to cancer has been estimated at 12%,
 62
 20%
 12
 and 30%
 63
 in 
different studies. 
Overtreatment is difficult to 
measure and to manage 
The majority of treatment is overtreatment, but as it is not possible to identify 
which lesions will regress this may not be resolvable with the technology 
currently available. 
There are vastly more abnormal results than there are invasive cancers, 
especially in women <25. E.g. in Australia in 2010 the incidence of invasive 
cancer in women <25 was 1.5/100,000, but 40,000 out of the 250,000 screens 
in women <25 returned an abnormal result.
64
 
Perinatal morbidity in treated women is the main iatrogenic harm of concern.
15
   
The evidence base is 
affected by differences in 
program design between 
countries 
Evidence about cervical screening comes mostly from monitoring data from 
screening programs. However, different countries run their programs 
differently. They use different tests, screening ages and screening intervals. 
They classify and report on their programs using different terminology and 
standards. Then the data from these very different contexts are combined. This 
has implications for the evidence base. 
Screening technology is 
changing 
Due to HPV vaccination a move away from cytology seems likely; an alternative 
future might be mass HPV screening with cytological examination of those with 
positive HPV tests. 
It is unclear what the incremental benefits and costs of these new technologies 
over existing screening programs will be. This is a rapidly evolving part of the 
evidence base in cervical screening. 
Table legend: CIN3 Cervical intra-epithelial neoplasia; HPV Human Papilloma Virus; LMICs Low and Middle 
Income Countries; RCT Randomized Controlled Trial. 
 
In addition, the treatments triggered by screening may be unnecessary and harmful in some 
cases. Cervical screening reduces cancer incidence as well as mortality. This is because it 
detects cellular abnormalities on the cervix, or pre-cancerous lesions, caused by human 
papillomavirus (HPV—Table 1). Cervical cancer is a rare outcome of persistent infection over 
a long time. However cellular abnormalities are common: there is an estimated lifetime 
incidence of 40% in women born since 1960.12  Also, progression appears to be less linear 
than originally thought,13 and most HPV infections regress spontaneously. This means 4/5 
women with dysplasia may be treated unnecessarily;12 but at present it is not possible to 
identify which individual high-grade lesions will regress (and so can be left untreated) or will 
progress (so require treatment–Table 2). 
 
The evidence does suggest a solution however: to focus on minimizing harm, particularly in 
women under age 25. The evidence shows that: a) HPV infection is most likely to 
spontaneously regress in this group; b) paradoxically, these women also experience more 
abnormal cytology, treatment, and cervical incompetence and perinatal morbidity as a 
result of treatment; and crucially c) there is no mortality benefit in screening this age 
group.14, 15 As a result, many countries are delaying commencement of screening until the 
age of 25 (Table 1) and/or recommending screening thereafter only every 3-5 years.16, 17 
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Although this change is supported by the evidence, in many jurisdictions women continue to 
be screened earlier and more often than these guidelines would support.5, 18, 19 
 
Finally, it is important to anticipate the future impact of new technologies on the evidence 
base and on practice.20, 21 Research increasingly supports screening women aged ≥30 using 
an oncogenic-type HPV test instead of or in addition to cytology.6 The US Preventive 
Services Taskforce (USPSTF), for example, now recommends that women aged 30 to 65 
years can screen with a combination of cytology and HPV testing every 5 years if they wish, 
rather than with cytology alone every 3 years.7 The FDA has recently approved the use of 
HPV testing alone as a primary screening test,22 which seems likely to result in further 
revision of recommendations. The recommendations are somewhat ahead of the evidence – 
with the exception of an Indian cluster RCT,8 primary HPV testing has not yet shown 
mortality benefit. Similarly, comparative benefits and harms of different sequential 
combinations of HPV and cytology testing are not yet clear. However RCTs of newer 
screening technologies (e.g. HPV tests, including self-testing and testing in vaccinated 
populations, and computer assisted cytology reading) are underway. HPV vaccination will 
further reduce underlying risk in the population and so potentially reduce the relevance of 
the existing evidence on cervical screening. 
 
Screening for prostate cancer 
Unlike cervical screening, prostate specific antigen (PSA) testing for prostate cancer risk is 
intensely contested;23 this includes contention over the relationship between evidence and 
practice. Important issues include: 
1) There is inconsistency between the findings of different trials (and tension over the 
interpretation of observational findings);  
2) Tests and thresholds for abnormality vary within and between studies; and 
3) The evidence suggests that the PSA test performs poorly for screening purposes. 
 
The first challenge is the quality and interpretation of research about the efficacy and 
effectiveness of PSA testing. Observational data from highly-screened communities is 
sometimes used to argue that testing reduces prostate cancer mortality.24-26 However, as 
noted earlier, findings from observational studies may be misleading because of 
characteristic biases such as lead time, length time, and selection bias.2, 27 Early RCTs were 
of poor quality (Table 3).2, 27 Since then, two ongoing RCTs have reported results: the 
European Randomized Study of Screening for Prostate Cancer (ERSPC), and the USA Prostate 
Lung Colorectal and Ovarian Cancer (PLCO) trial. PLCO has shown no effect on prostate 
cancer-specific or all-cause mortality.28 ERSPC reported reduced prostate cancer mortality in 
screened men but no change in all-cause mortality.29 There is considerable controversy over 
trial design (Table 3). Although difficult to quantify, frequency of testing and follow-up, and 
type of treatment provided after diagnosis, are likely to affect outcomes reported from 
trials.30-32  
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Table 3 Main issues in prostate cancer screening 
Issue Explanation  
Most prostate cancer is not 
life threatening 
Although prostate cancer can be life threatening, the vast majority of cases are 
indolent.  
Early trials of PSA screening 
were of poor quality 
Early trials—which reported very positive findings—had serious 
methodological problems, including low participation in screening, failure to 
randomise, and failure to analyse by intention to screen.  
Large RCTs are currently 
underway 
ERSPC trial, and the USA PLCO trial have made interim reports but are ongoing. 
These are the only large, methodologically sound trials of PSA screening 
conducted to date. 
There is controversy over 
the design of the current 
large RCTs 
ERSPC included different countries using different screening tests and 
procedures. Those screened in the trial were more likely to be treated in a 
University hospital. The Swedish subset of ERSPC compared volunteer 
screenees (probably a healthier group) to whole-population controls 
(particularly significant because Sweden was one of only two, out of seven, 
subgroups to report statistically significant reductions in prostate cancer 
mortality after 11 years. These patterns likely to bias results in favour of 
screening.  
In PLCO, >50% of controls were screened during the trial, 44% of participants 
had previously been screened. 
Methodologists disagree on whether these biases are fatal to the results of the 
trials.  
PSA screening may 
decrease prostate cancer 
death 
Some trials suggest reductions in incidence of prostate cancer death. 
Observational studies in highly-screened populations suggest lower prostate 
cancer mortality. 
PSA screening is unlikely to 
decrease all-cause mortality 
Only ERSPC has reported a mortality benefit, which was very small in absolute 
terms. 1055 men would have to be screened to prevent one death from 
prostate cancer over 11 years.
30
 
The PSA test is not prostate 
cancer-specific 
PSA test has poor sensitivity and specificity for detecting prostate cancer. A 
PSA >4.0ng/ml produces a 6.2% false positive rate but detects only 20.5% of 
cancer cases.
65
 
PSA test cannot distinguish increased cancer risk from other common 
conditions e.g. benign prostatic hyperplasia, prostatitis. 
Certain medications (e.g. finasteride), ejaculation, and prostate manipulation 
can also increase PSA levels. 
PSA test manufacturers and 
PSA thresholds vary 
between studies, 
laboratories, and clinicians 
Studies and laboratories employ more than one kind of PSA test and different 
abnormal thresholds. 
The evidence base is thus hard to interpret due to lack of comparability. 
Conventional threshold for further investigation is 4ng/mL, but men with PSA 
levels 4-10ng/ml may not have prostate cancer,
66
 and men with results 
<4ng/mL can show histological evidence of prostate cancer.
25, 67
 
Lowering the threshold below 4ng/mL would increase overdiagnosis and 
overtreatment of clinically unimportant disease.
27, 68
 
A meaningful threshold for screening may not exist because of the test’s poor 
sensitivity and specificity i.e. the PSA test has little utility as a screening tool for 
prostate cancer. There is currently no alternative test available.  
PSA screening can increase 
the likelihood of receiving 
treatment 
In the USA, for example, up to 90% of men with prostate cancer diagnosed as a 
result of PSA testing receive treatment.
56
  
Prostate cancer treatment 
can produce considerable 
negative consequences  
Treatment can result in erectile dysfunction or impotence, anxiety, urinary 
incontinence, bowel dysfunction, or death. 
Table Legend: ERSPC European Randomized Study of Screening for Prostate Cancer; PLCO Prostate Lung 
Colorectal and Ovarian Cancer trial; PSA Prostate Specific Antigen. 
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Expert bodies increasingly advise against PSA screening. The USPSTF concluded that the 
mortality benefit is very small and outweighed by risk of harm.33 The American College of 
Preventive Medicine has similarly concluded that populations should not be routinely 
screened with the PSA test, due to insufficient evidence.34 The Australian National Health 
and Medical Research Council evidence guideline on PSA testing in asymptomatic men has 
recently concluded that there is no effect of PSA testing on all-cause mortality, and that no 
conclusions can be drawn about prostate cancer mortality.35 These decisions are consistent 
with the evidence, which suggests that PSA testing may reduce the short term risk of dying 
from prostate cancer by a very small amount, at the cost of a much greater risk of harm, 
including from false positive results, overdiagnosis and overtreatment. The question this 
raises is: if a screened man will not die any later than an unscreened man, is it meaningful to 
prevent him from dying of prostate cancer in particular? And at what cost (harms to the 
man as well as expense to the man and the health system) should this goal be pursued? This 
question seems to divide experts, not least according to whether they care for men with the 
disease or have experienced it themselves. 
 
The second problem in the PSA testing evidence is interpretability and comparability of PSA 
results. This is an issue for many screening tests (see Table 1), but especially for the PSA 
test. Manufacturers and laboratories employ divergent PSA calibrations, producing different 
PSA readings from the same sample.36 Even when identical methods are used, thresholds 
set to separate ‘normal’ from ‘high risk’ PSA levels often differ. Within and between studies 
different standards are often combined, potentially invalidating conclusions.25, 37 Tests and 
thresholds used by different countries participating in large trials often vary (Table 3), and 
trial study groups have been unable to identify acceptable PSA cut-off points for prostate 
cancer screening. This makes it difficult to compare study results and apply them to real-life 
settings. 
 
The final problem with interpreting the evidence about PSA testing is addressing the 
potential for harm. The evidence suggests that sensitivity and specificity of the test are poor 
(Tables 1 & 3), which means cancers are missed (poor sensitivity) and false positives are 
common (poor specificity). The evidence suggests that PSA testing increases diagnosis of 
indolent disease, frequently cascades to diagnostic biopsies and follow-up treatments, and 
produces physical and psychological harms and costs: for every life saved by the PSA test, up 
to 48 men may be overtreated (Table 3).38 Determining whether this is acceptable requires 
difficult debate over the nature of a good outcome, and what harm or expense that 
outcome might justify. 
 
Screening for breast cancer 
Like the evidence for PSA testing, the evidence for breast screening has been controversial. 
Important features of this evidence base include: 
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1) Uncertainty regarding the extent of breast cancer mortality reduction benefit; 
2) Uncertainty regarding the extent of harm; and 
3) Disagreement about managing in situ disease. 
 
The first challenge for the evidence on breast screening is that despite a considerable body 
of research, the degree to which breast screening reduces breast cancer mortality remains 
unclear. The evidence base includes 11 RCTs (1971-2006), numerous observational studies, 
and mathematical models.  It is probable that an invitational program of breast screening by 
mammography offers a population breast cancer mortality benefit, particularly for women 
aged 50-70. If poorer-quality RCTs are removed from meta-analyses this benefit is reduced. 
By how much is unclear (Table 4). Absolute and relative benefits are lower in women aged 
<50.39 Also, treatment has greatly improved in recent decades, so including RCTs from the 
1970s–1990s may overstate the benefit of screening (Table 4).1, 40-44 The degree to which 
widely-observed declines in breast cancer mortality are attributable to improvements in 
treatment remains contested.45 It is unclear how this can be resolved. Incremental changes 
in technology—from film mammography to digital mammography, tomosynthesis 
(integrated 2/3D mammography) and MRI to screen high risk women—may also affect the 
balance of screening benefits and harms.46, 47 
Table 4 Main issues in breast cancer screening 
Issue Explanation  
Mortality 
benefit exists 
Most studies show mortality benefit from organised mammographic screening, especially 
for women aged 50-70, of approximately 20%.
40-43
 
The extent of 
mortality benefit 
is contentious 
Estimates of benefit vary considerably. 
Different study types are used including RCTs, observational studies and modelling. 
Meta-analysis of RCTs is widely regarded as the best way to identify population benefits, 
but different meta-analyses include or exclude different RCTs due to differing judgements 
about study quality.
40-43
 
Mortality 
benefit is less 
than originally 
thought  
Recent meta-analyses of RCTs suggest that benefit is lower than suggested by the earliest 
studies. 
This can be partly attributed to problems in quality with some of the RCTs. 
It has been hypothesised that treatment improvements in recent decades may leave less 
room for screening to have an effect and make older trial data less relevant.
40-43 
 
The harm from 
false positive 
screening tests 
varies between 
programs and 
populations  
The rate of false positives varies as a result of factors such as: 
 Test factors e.g. equipment quality; skill of the clinicians reading the mammograms. 
 Differing policies and standards regarding acceptable levels of false positives and false 
negatives. 
 Frequency of screening in the program (increased frequency tends to increase the 
absolute number of false positives). 
 Individual participant factors (e.g. greater breast density in some women, including 
pre-menopausal women and women taking hormone replacement therapy (HRT)) 
which can make mammogram interpretation more challenging (and false positives 
more common). 
 Population factors: the frequency of false positives in part depends on the positive 
predictive value of the test, which depends on the prevalence of disease in the 
screened population. This depends on population risk profile (e.g. younger women 
have lower incidence).
48
 
The extent of 
overdiagnosis is 
contentious 
Estimates of overdiagnosis vary as a result of factors including the population studied, 
research questions asked (e.g. total cancer or invasive cancer only), methods used (e.g. 
comparing incidence in intervention and control arms of RCTs, comparing observational 
annual incidence data, comparing observational cumulative incidence data, using 
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simulated population models), correction for possible biases such as lead time, and 
fundamental assumptions when estimating overdiagnosis in models.
1, 15, 44, 50
  
Biological 
consequences of 
in situ disease is 
unclear 
 
Before the onset of screening, in situ disease was mostly diagnosed in conjunction with an 
invasive cancer. It was not anticipated to be a common isolated finding on screening. 
It is unclear what the right response to increased diagnosis of in situ disease should be. 
Knowledge of the natural history of in situ breast diseases is improving but still 
incomplete. 
Diagnosis and management are controversial, especially for less aggressive diseases (e.g. 
low grade DCIS) where risk of death is only slightly increased but surgery to negate the risk 
may be extensive.
40-43 
 
There are small 
radiation harms 
of screening  
Harms from radiation during mammography are generally agreed to be real, and may be 
greater in women screened more often (e.g. those identified as carrying potentially 
harmful mutations in the BRCA1 or BRCA2 genes).
69, 70
 However in screening of the general 
population, these risks are extremely small, and likely to be further reduced by the 
implementation of digital mammography. 
BRCA1/BRCA2 BReast CAncer susceptibility gene 1 and 2; DCIS Ductal Carcinoma In Situ; RCT Randomised 
Controlled Trial. 
 
The second concern is the extent of harm caused. Invitational mammography programs 
cause harm, including from false positives and overdiagnosis. The absolute rate of false 
positives can vary according to equipment used, skill and experience of film readers, test 
thresholds and screening frequency (Table 4).48 Although the rate of false positives per 
screen may be low, they accumulate, so the chance of false positive recall or biopsy over a 
lifetime is much higher. Increasingly, evidence suggests that breast screening produces 
overdiagnosis of both invasive and in situ breast cancer. Although experts agree that 
mammography screening causes overdiagnosis, there is disagreement on its extent. A 
recent meta-analysis suggests that, in women invited to screening, there is an 11% lifetime 
risk of overdiagnosis as a proportion of cancers diagnosed, and a 19% risk during the active 
screening period.40, 43 Harms, especially overdiagnosis, may tend to outweigh benefits in 
women >70 as they age.49 However the relevant evidence is highly contentious for 
methodological and other reasons explained in Table 4.44, 50  
 
The final challenge in this evidence base concerns ductal carcinoma in situ (DCIS), which 
represents approximately 17% to 34% of screen-detected cases and 20%–25% of all newly 
diagnosed cases of breast cancer in the USA.51 Women are rarely diagnosed with DCIS 
because they experience symptoms: DCIS is diagnosed almost entirely as a result of 
screening. Overdiagnosis of DCIS is considered by many an important harm of 
mammographic screening. However the evidence is not clear on either the natural history of 
DCIS or how aggressively DCIS should be treated. More research is needed to evaluate 
treatments for in situ disease.40, 44 
 
What characteristics of the screening evidence base could explain expert disagreement? 
In high-income countries, cancer screening is a familiar feature of preventive medical care. 
Screening is expected—with good reason—to be informed by evidence. Across these three 
cases, there are two less-often discussed tensions and three more explicit tensions that help 
to explain why interpreting the evidence is such a difficult task. 
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Tensions in the evidence base that are less-often discussed 
Two tensions in the evidence base are under-examined: the comparability of data between 
studies and contexts, and the impact of technological developments. These tensions are 
also difficult to resolve and potentially destabilizing. 
 
Data from very different contexts may not be comparable 
Data from different contexts may not be comparable, particularly for observational data 
from monitoring studies. As shown, the evidence base contains data from different times, 
countries and programs, and from populations with varying event rates (Table 1). 
Transferability of this evidence is difficult for several reasons. Because screening trials are 
particularly large and need long follow-up to show effects, they can be especially susceptible 
to the passage of time. When early trials were conducted, screening techniques were less 
developed, treatments less effective, cancer incidence lower and cancer mortality often 
higher. (Breast screening evidence, for example, includes decades-old trials: treatment has 
progressed substantially since they were conducted.) Evidence from screening trials is also 
susceptible to local variation (e.g. in disease biology, event rates and age distribution), not 
least because screening is applied to whole populations, not just people who are ill. (As HPV 
vaccination is implemented differently around the world, for example, the underlying event 
rate for cervical cancer will change dramatically.) The resource intensiveness of cancer 
screening trials also means that: 1) few trials are done (leaving less evidence to interpret); 2) 
trials are often funded by industry (changing the research questions asked); and 3) trials are 
somewhat dependent on local screening and treatment practices (e.g. target age, screening 
intervals, testing techniques, follow-up time, available treatment). The variability and 
transferability of screening evidence is a challenge for methodologists; even more so for 
clinicians and policymakers, as the characteristics on which the evidence depends are not 
always made clear in reporting.  
 
Screening technologies affect evidence quality, evidence must evolve with changing 
technologies 
Cancer screening relies on complex cascades of technology for collecting, imaging, analysing 
and interpreting possible changes in human bodies. Without the technology, there is no 
screening, but as technology evolves, it potentially makes existing evidence obsolete.52 
 
The evidence on PSA is hampered by poor technology. The PSA test has limited sensitivity 
and specificity, studies and laboratories use multiple test types and different thresholds, 
there is no meaningful ‘normal range’, and new test rules do not appear to change patient 
outcomes. Some propose using test results only within, rather than between, patients, but 
the poor test characteristics of PSA make even this problematic. It is understandable that 
clinicians want to retain some tool to measure prostate cancer risk.53 But given the test 
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characteristics of the PSA, it may not be possible to generate a meaningful evidence base 
about its use in populations. 
 
The cervical screening evidence base is shifting because of changing technology; tests that 
detect oncogenic-type HPV may become the primary form of screening in vaccinated 
populations. Mammography remained relatively constant in the 20th Century, changing only 
incrementally from film to digital mammography. In the 21st Century we face substantial 
technological change, with moves to tomosynthesis (integrated 2/3D mammography) and 
MRI screening of high risk women.  Although tomosynthesis is receiving considerable 
attention in the lay press and peer reviewed literature, attempts to estimate its effects have 
been based on opaque assumptions and limited evidence. It seems possible that both MRI 
and tomosynthesis will enhance both the benefits and harms of screening, but at present 
this is unknown.46, 47 
Acknowledged tensions in the evidence base 
Three other, more explicit, tensions are over the quality of evidence of benefit, the 
relatively new evidence regarding screening harms, and risk communication. 
 
The quality of evidence of benefit varies, and the implications are contested 
When one expert says to another ‘you are wrong about the evidence on screening’, she is 
likely to mean this: ‘I disagree with the criteria that you have used to separate good-quality 
studies, which should be included, from poor-quality studies, which should be excluded. I 
therefore disagree with your conclusion.’ 
The cancer screening evidence base contains observational studies, RCTs, and modelling, of 
widely varying quality, and with disparate results. Early studies of screening generally 
suggested greater benefit, and later studies less benefit, which may be because early trials 
were poorly designed (e.g. PSA) or because recent treatment improvements leave less room 
for screening to provide benefit (e.g. breast screening). Even new trials contain 
methodological flaws (e.g. PLCO, ERSPC), and methodologists often disagree about study 
design, particularly over whether screened and unscreened groups are comparable.  
 
New RCTs are expensive and logistically challenging, so are rare. Thus new conclusions 
generally arise from reanalyses of existing research findings rather than from new trials. 
Researchers performing meta-analyses must decide on criteria for including and excluding 
studies. The recent Marmot review of the evidence on breast screening demonstrates that 
this is possible,40 even in high-profile situations, but disagreement over criteria is likely to 
remain. And when new analyses produce new findings, those whose settled beliefs are 
challenged may perceive the chosen criteria as arbitrary or incorrect. This highlights the 
importance of transparency regarding how and why meta-analyses are conducted. 
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Evidence about harms is relatively new, there are gaps in that evidence, and disagreement 
about what it means 
Initially, cancer screening researchers focused on measuring screening benefits; they have 
only recently turned to potential harms. For all three cases—cervical, prostate and breast 
cancer (including DCIS)—there is limited evidence about which instances of disease or pre-
disease are aggressive, so require treatment, and which will be indolent or regress.  Because 
of this, many people will be over-treated, and may be harmed. Researchers are trying to 
address this gap, by studying the mortality benefit of treatment for small, grade 1, node 
negative breast cancers, for example, or the genetic profile of aggressive versus indolent 
prostate cancers. This work may assist in future. In the meantime, existing knowledge 
suggests opportunities to reduce harm. For example, there is currently no way to determine 
which cervical lesions will regress or progress. However epidemiological data demonstrates 
that women 18-25 are most likely to have unnecessary treatment, experience harms from 
treatment, and fail to benefit from treatment. This has led some jurisdictions to restrict 
cervical screening to women aged over 25. 
 
Even when evidence about screening harms emerges, experts often disagree about what it 
means and how to respond. This may be in part because public health and medical 
professionals have learned to think in a particular way, and have taught citizens to think 
similarly, of cancer and pre-cancer as progressive and life-threatening, and screening as one 
of few defences against this threat. For the first several decades of screening research, 
harms were rarely measured. Although later research suggested that screening may harm, it 
may be difficult for this evidence to reach public attention given the powerful cultural 
meaning of cancer death.54, 55 New facts about screening harms are hotly contested, with 
regard both to their accuracy and their implications. And screening programs continue to be 
evaluated primarily against increasing participation targets, rather on the likely balance 
between benefit and harm achieved.  
 
For example, it is generally accepted that prostate biopsies and prostate cancer treatments 
are likely to produce harms. This is taken as a fact, but that fact is interpreted very 
differently. Some argue that most screen-detected prostate cancers are indolent, so most 
diagnosis is overdiagnosis, and most harm done is unnecessary harm. They conclude that 
insurers or policymakers should constrain clinicians who test healthy men, thus preventing 
harm. Others take a different view, that without PSA testing clinicians have no way of 
diagnosing tumours that would develop or metastasize. These experts tend to take the view 
that insurers or policymakers should leave testing open to clinicians, and allow the 
possibility of harm to be dealt with via more judicious decisions about treatment. Their 
opponents might counter with studies showing that men diagnosed with prostate cancer 
generally proceed to treatment  rather than ‘watching and waiting’.56 Although each party 
can present data of some kind to support their claims, it is worth remembering that data 
become evidence only through interpretation, and that experts are susceptible to biases in 
this interpretive process.57, 58 
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Evidence about outcomes is often poorly communicated, despite the evidence about 
communication 
Researchers and programs tend to express outcomes using relative risks, which incorporate 
baseline risk and so are easier to generalize across contexts. However research shows that 
relative risks encourage lay people and clinicians to overemphasize benefits and minimize 
harms. This has been acknowledged as ethically problematic, potentially biasing or 
manipulating people’s perceptions, misleading them, and undermining their autonomy.59 If 
experts are obliged to communicate honestly with citizens—an obligation that seems 
supportable—this becomes an urgent issue to address for all forms of cancer screening. 
 
Conclusions 
The benefits and harms of screening are often finely balanced; more than anticipated when 
screening was established. There are both unique and shared characteristics of cervical, 
prostate and breast screening that help to explain the challenge of balancing benefit and 
harm. These include the incomparability of data from different times, places and programs, 
the instability of the very technology on which screening is based, disagreement on which 
studies are well-enough designed to be taken seriously, gaps in knowledge, and 
disagreement about how to understand newly emerging evidence of harm. This suggests 
five principles for evaluating and using the evidence:  
 
1) attend closely to transferability;  
2) consider the influence of technologies on the evidence base;  
3) query the design of meta-analyses;  
4) ensure harms are defined and measured; and  
5) improve risk communication practices.  
 
However even more fundamental are questions about the purpose of screening, and who 
should make decisions about screening. Should insurers or policymakers leave screening 
options open for clinicians and patients to choose? Or should they be directive, promoting 
some forms of screening and limiting others to minimize harm? Should community 
engagement and deliberation guide screening policy and practice? And what should the 
purpose of screening be? There are many potential aims of cancer screening, including 
preventing cancer death, reducing all-cause mortality, minimizing anxiety, maximizing cost 
efficiency and/or minimizing avoidable harm. These different aims reflect different values, 
values that may differ between patients, clinicians, funders and policymakers. Questions 
about the evidence base need resolution. This should be complemented with clear thinking 
about the aims of screening. Only when the aims of screening are clear will researchers be 
able to generate an evidence base sufficient to assist decision-making, and clinicians be able 
to best support their patients to make good screening decisions.   
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